A multicenter clinical trial found that intramuscular sotrovimab matched intravenous administration in reducing viral load among outpatients with early mild-to-moderate COVID-19. The study specifically compared viral clearance kinetics between the delivery routes, addressing an access and administration challenge for antibody therapies. The results strengthen the case for alternative administration pathways that can simplify outpatient delivery while preserving virologic efficacy signals during early infection.
Get the Daily Brief